MARKET

ONCY

ONCY

Oncolytics Biotech Inc
NASDAQ
1.060
+0.030
+2.91%
After Hours: 1.060 -0.001 -0.05% 19:46 03/28 EDT
OPEN
1.040
PREV CLOSE
1.030
HIGH
1.060
LOW
1.010
VOLUME
294.22K
TURNOVER
0
52 WEEK HIGH
3.394
52 WEEK LOW
0.8830
MARKET CAP
79.94M
P/E (TTM)
-3.4216
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ONCY last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at ONCY last week (0311-0315)?
Weekly Report · 03/18 10:32
Biotech's Role in Addressing the Pancreatic Cancer Emergency
Pancreatic cancer still has the highest mortality rate of all major cancers. American Cancer Society projecting a record year for new cancer cases in 2024. Researchers and the biotech sector are working diligently to improve the chances of those diagnosed with pancreatic cancer. Researchers at the Mayo Clinic made a discovery that advances knowledge of how the cancer spreads.
Barchart · 03/14 07:45
Weekly Report: what happened at ONCY last week (0304-0308)?
Weekly Report · 03/11 10:30
Buy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment Trials
TipRanks · 03/09 17:25
Buy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical Trials
TipRanks · 03/08 21:25
Oncolytics Biotech Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/08 18:14
Oncolytics Biotech Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 03/08 18:14
More
About ONCY
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Webull offers Oncolytics Biotech Inc (USA) stock information, including NASDAQ: ONCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCY stock methods without spending real money on the virtual paper trading platform.